First, we found that RAGE is associated with worse BC-specific survival (Fig. 1A, B) and worse clinicopathological features in BC patients, as evidenced by a higher gene expression of RAGE in patients affected by stage II-III vs stage I BC (Fig. 1C). This evidence concerns the gene AGER and breast cancer.